- Home
- LCTX vs ALCY Comparison
LCTX vs ALCY Comparison
Compare LCTX & ALCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- ALCY
- Stock Information
- Founded
- LCTX 1990
- ALCY 2021
- Country
- LCTX United States
- ALCY United States
- Employees
- LCTX N/A
- ALCY N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- ALCY Blank Checks
- Sector
- LCTX Health Care
- ALCY Finance
- Exchange
- LCTX Nasdaq
- ALCY Nasdaq
- Market Cap
- LCTX 165.6M
- ALCY 160.9M
- IPO Year
- LCTX N/A
- ALCY 2023
- Fundamental
- Price
- LCTX $0.88
- ALCY $10.87
- Analyst Decision
- LCTX Strong Buy
- ALCY
- Analyst Count
- LCTX 3
- ALCY 0
- Target Price
- LCTX $5.67
- ALCY N/A
- AVG Volume (30 Days)
- LCTX 294.4K
- ALCY 45.3K
- Earning Date
- LCTX 11-07-2024
- ALCY 01-01-0001
- Dividend Yield
- LCTX N/A
- ALCY N/A
- EPS Growth
- LCTX N/A
- ALCY N/A
- EPS
- LCTX N/A
- ALCY 0.36
- Revenue
- LCTX $6,186,000.00
- ALCY N/A
- Revenue This Year
- LCTX N/A
- ALCY N/A
- Revenue Next Year
- LCTX $119.00
- ALCY N/A
- P/E Ratio
- LCTX N/A
- ALCY $29.94
- Revenue Growth
- LCTX N/A
- ALCY N/A
- 52 Week Low
- LCTX $0.77
- ALCY $10.31
- 52 Week High
- LCTX $1.61
- ALCY $11.85
- Technical
- Relative Strength Index (RSI)
- LCTX 47.12
- ALCY 61.35
- Support Level
- LCTX $0.83
- ALCY $10.85
- Resistance Level
- LCTX $0.94
- ALCY $10.86
- Average True Range (ATR)
- LCTX 0.05
- ALCY 0.01
- MACD
- LCTX 0.00
- ALCY 0.00
- Stochastic Oscillator
- LCTX 45.45
- ALCY 71.57
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About ALCY Alchemy Investments Acquisition Corp 1
Alchemy Investments Acquisition Corp 1 is a blank check company.